United Therapeutics (UTHR) Other Non-Current Liabilities (2009 - 2026)

United Therapeutics has reported Other Non-Current Liabilities for 18 years, with the latest figure at $214.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 0.56% year-over-year to $214.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $214.0 million (down 0.56% YoY) and the FY2025 annual result came in at $223.2 million, up 22.7% from the prior year.
• Other Non-Current Liabilities retreated to $214.0 million in Q1 2026 per UTHR's latest filing, from $223.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $223.2 million in Q4 2025 and troughed at $67.4 million in Q3 2023.
• A 5-year average of $137.1 million and a median of $103.5 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities sank 34.88% in 2023, then jumped 133.8% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $104.6 million in 2022, then decreased by 25.62% to $77.8 million in 2023, then surged by 133.8% to $181.9 million in 2024, then climbed by 22.7% to $223.2 million in 2025, then dropped by 4.12% to $214.0 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $214.0 million, $223.2 million, and $214.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.